drugset / Trial / NCT05224401

Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs

NCT05224401

Phase 3 Recruiting 330 enrolled Lund University
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate if the combination of pivmecillinam and clavulanic acid (PAC) is non-inferior to ciprofloxacin, trimethoprim-sulfamethoxazole or ertapenem as step down oral therapy in patients with febrile UTI caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales (EPE).

Timeline

Start
2023-05-29
Primary completion
2027-09-01
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 500 mg Oral
Subject Amoxicillin Other / unclassified 875 mg Oral
Comparator Ciprofloxacin Small molecule 500 mg Oral
Comparator Ertapenem Small molecule 1 g Intravenous
Subject Pivmecillinam Small molecule 400 mg Oral
Comparator Sulfamethoxazole Small molecule 160 mg Oral
Comparator Trimethoprim Small molecule 800 mg Oral
Subject clavulanic acid Small molecule 125 mg Oral